Literature DB >> 17394021

Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth.

Ravi Retnakaran1, Philip W Connelly, Stewart B Harris, Bernard Zinman, Anthony J G Hanley.   

Abstract

Serum concentration of cystatin C, a marker of glomerular filtration, has been associated with incident cardiovascular disease (CVD), although the pathophysiology underlying this association remains unclear. As North American Aboriginal populations are experiencing high prevalence rates of CVD in early adulthood, evaluation of cardiovascular (CV) risk factors in Aboriginal children may provide insight into the early pathophysiology of vascular disease. In this context, we sought to determine whether cystatin C is associated with CV risk factors in Aboriginal youth. Serum concentrations of cystatin C were assessed in a population-based study of a Canadian Aboriginal community, involving 230 children aged 10-19 years. Cystatin C was higher in the 41 children with pediatric metabolic syndrome (MetS) (defined using an age- and gender-specific version of Adult Treatment Panel III criteria) than in the 189 children free of MetS (0.87 vs 0.81 mg/l, p = 0.0026). After adjustment for age, gender, and glomerular filtration rate (estimated using the Schwartz formula), cystatin C was (1) positively correlated with waist circumference, body mass index, systolic blood pressure, triglycerides, fasting insulin, and leptin (all r >/= 0.18, p < 0.05), and (2) inversely related to high-density lipoprotein (HDL) cholesterol (r = -0.21, p = 0.0023). These associations, however, were attenuated with further adjustment for insulin resistance, as measured by the homeostasis model assessment (HOMA-IR). On multivariate analysis, waist circumference emerged as a positive independent determinant of cystatin C, whereas female gender and age were negative correlates. Cystatin C levels progressively increased in association with the number of metabolic syndrome component disorders coexistent within an individual (trend p = 0.0072). In summary, increased cystatin C is associated with an enhanced CV risk factor profile in Aboriginal youth and may be an early event in the natural history of vascular disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17394021     DOI: 10.1007/s00467-007-0471-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  33 in total

1.  Increasing rates of ischemic heart disease in the native population of Ontario, Canada.

Authors:  B R Shah; J E Hux; B Zinman
Journal:  Arch Intern Med       Date:  2000-06-26

2.  Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study.

Authors:  Ann M O'Hare; Anne B Newman; Ronit Katz; Linda F Fried; Catherine O Stehman-Breen; Stephen L Seliger; David S Siscovick; Michael G Shlipak
Journal:  Arch Intern Med       Date:  2005 Dec 12-26

3.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

4.  The prevalence of NIDDM and associated risk factors in native Canadians.

Authors:  S B Harris; J Gittelsohn; A Hanley; A Barnie; T M Wolever; J Gao; A Logan; B Zinman
Journal:  Diabetes Care       Date:  1997-02       Impact factor: 19.112

5.  Elevated C-reactive protein in Native Canadian children: an ominous early complication of childhood obesity.

Authors:  R Retnakaran; A J G Hanley; P W Connelly; S B Harris; B Zinman
Journal:  Diabetes Obes Metab       Date:  2006-09       Impact factor: 6.577

6.  Cigarette smoking and cardiovascular risk factors among Aboriginal Canadian youths.

Authors:  Ravi Retnakaran; Anthony J G Hanley; Philip W Connelly; Stewart B Harris; Bernard Zinman
Journal:  CMAJ       Date:  2005-10-11       Impact factor: 8.262

7.  Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.

Authors:  Wolfgang Koenig; Dorothee Twardella; Hermann Brenner; Dietrich Rothenbacher
Journal:  Clin Chem       Date:  2004-11-24       Impact factor: 8.327

8.  A simple estimate of glomerular filtration rate in adolescent boys.

Authors:  G J Schwartz; B Gauthier
Journal:  J Pediatr       Date:  1985-03       Impact factor: 4.406

9.  Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey.

Authors:  Sarah D de Ferranti; Kimberlee Gauvreau; David S Ludwig; Ellis J Neufeld; Jane W Newburger; Nader Rifai
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

10.  Indexes of insulin resistance and secretion in obese children and adolescents: a validation study.

Authors:  Louise S Conwell; Stewart G Trost; Wendy J Brown; Jennifer A Batch
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

View more
  12 in total

Review 1.  Association of cystatin C with adverse outcomes.

Authors:  Magdalena Madero; Mark J Sarnak
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-05       Impact factor: 2.894

2.  Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease.

Authors:  Jan A Krikken; Ron T Gansevoort; Robin P F Dullaart
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

3.  Cystatin C, cardiometabolic risk, and body composition in severely obese children.

Authors:  Pilar Codoñer-Franch; Esther Ballester-Asensio; Lorena Martínez-Pons; Jorge Vallecillo-Hernández; Almudena Navarro-Ruíz; Ramón del Valle-Pérez
Journal:  Pediatr Nephrol       Date:  2010-11-19       Impact factor: 3.714

4.  Implications for kidney disease in obese children and adolescents.

Authors:  Alessandra Savino; Piernicola Pelliccia; Cosimo Giannini; Tommaso de Giorgis; Ivana Cataldo; Francesco Chiarelli; Angelika Mohn
Journal:  Pediatr Nephrol       Date:  2011-02-11       Impact factor: 3.714

5.  Association of visceral and subcutaneous adiposity with kidney function.

Authors:  Jill A Young; Shih-Jen Hwang; Mark J Sarnak; Udo Hoffmann; Joseph M Massaro; Daniel Levy; Emelia J Benjamin; Martin G Larson; Ramachandran S Vasan; Christopher J O'Donnell; Caroline S Fox
Journal:  Clin J Am Soc Nephrol       Date:  2008-09-24       Impact factor: 8.237

6.  Relationship between cystatin C and coronary artery atherosclerosis progression differs by type 1 diabetes.

Authors:  David M Maahs; Janet K Snell-Bergeon; John E Hokanson; Gregory L Kinney; Tomas Berl; Marian Rewers; Lorraine G Ogden
Journal:  Diabetes Technol Ther       Date:  2010-01       Impact factor: 6.118

7.  Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate.

Authors:  Xie Qing; Wang Furong; Liu Yunxia; Zhang Jian; Wang Xuping; Gao Ling
Journal:  Cardiovasc Diabetol       Date:  2012-09-14       Impact factor: 9.951

8.  Exercise electrocardiographic responses and serum cystatin C levels among metabolic syndrome patients without overt diabetes mellitus.

Authors:  Asli Tanindi; Hilal Olgun; Ayse Tuncel; Bulent Celik; Hatice Pasaoglu; Bulent Boyaci
Journal:  Vasc Health Risk Manag       Date:  2011-02-06

9.  Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study).

Authors:  Razieh Hassannejad; Hamsa Sharrouf; Fahimeh Haghighatdoost; Ben Kirk; Farzad Amirabdollahian
Journal:  Nutrients       Date:  2021-06-30       Impact factor: 5.717

10.  Body mass index and early kidney function decline in young adults: a longitudinal analysis of the CARDIA (Coronary Artery Risk Development in Young Adults) study.

Authors:  Vanessa Grubbs; Feng Lin; Eric Vittinghoff; Michael G Shlipak; Carmen A Peralta; Nisha Bansal; David R Jacobs; David S Siscovick; Cora E Lewis; Kirsten Bibbins-Domingo
Journal:  Am J Kidney Dis       Date:  2013-12-02       Impact factor: 11.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.